Inyx, Inc., a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, has signed a letter of intent with NovaDel Pharma Inc., whereby Inyx, will serve as NovaDel's partner of choice to manufacture, for worldwide markets, three additional products from NovaDel's product pipeline.

On November 23, 2004, Inyx was awarded an exclusive five-year contract to produce NovaDel's nitroglycerin lingual spray for the treatment of acute angina, the first of NovaDel's Tier One priority products to reach the stage of New Drug Application review by the US Food and Drug Administration, a release stated.

Jack Kachkar, chairman and CEO of Inyx, said, "We are pleased with our expanding, long-term relationship with NovaDel. We look forward to NovaDel being one of our important new clients for whom we will be producing out of the Manati, Puerto Rico production complex that Inyx is acquiring from sanofi-aventis Group."

On December 17, 2004, Inyx signed a definitive agreement with Aventis Pharmaceuticals, Inc., a member of the sanofi-aventis Group, to acquire certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc. The acquisition of the Manati complex, which consists of five buildings totalling about 140,000 square feet and extends over 9.5 acres, is scheduled to close on March 31, 2004.

Inyx, Inc. is a specialty pharmaceutical company with aerosol drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.